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Abstract
Barbiturates potentiate GABA actions at the GABAA receptor and act as central nervous system depressants that can induce
effects ranging from sedation to general anesthesia. No structural information has been available about how barbiturates
are recognized by their protein targets. For this reason, we tested whether these drugs were able to bind specifically to
horse spleen apoferritin, a model protein that has previously been shown to bind many anesthetic agents with affinities that
are closely correlated with anesthetic potency. Thiopental, pentobarbital, and phenobarbital were all found to bind to
apoferritin with affinities ranging from 10–500 mM, approximately matching the concentrations required to produce
anesthetic and GABAergic responses. X-ray crystal structures were determined for the complexes of apoferritin with
thiopental and pentobarbital at resolutions of 1.9 and 2.0 A ˚, respectively. These structures reveal that the barbiturates bind
to a cavity in the apoferritin shell that also binds haloalkanes, halogenated ethers, and propofol. Unlike these other general
anesthetics, however, which rely entirely upon van der Waals interactions and the hydrophobic effect for recognition, the
barbiturates are recognized in the apoferritin site using a mixture of both polar and nonpolar interactions. These results
suggest that any protein binding site that is able to recognize and respond to the chemically and structurally diverse set of
compounds used as general anesthetics is likely to include a versatile mixture of both polar and hydrophobic elements.
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Introduction
General anesthetics, either inhaled or injected, are mainstays of
modern surgery. They are widely used to reversibly decrease
patients’ sensation of otherwise painful and unpleasant medical
procedures. General anesthetics function by decreasing synaptic
transmission of action potentials, primarily within the central
nervous system. Overdoses of anesthetics, though rare in clinical
practice, are potentially lethal as these drugs progressively recruit
other ‘‘off-pathway’’ actions, such as cardiovascular and respira-
tory depression.
The original anesthetic agents were discovered serendipitously
and then served as lead compounds for a decades-long process that
has resulted in the more efficacious and somewhat safer agents that
are used today. This progress occurred without definitive
knowledge of the pharmacological targets of these drugs; indeed,
even today questions remain as to which targets are the most
clinically relevant. However, it is widely believed that general
anesthetics act at multiple protein sites [1] and that these sites
include membrane-bound channel proteins within the central
nervous system. Likely candidates include the Cys-loop ligand-
gated ion channels [2,3], some potassium channels [4], and the
mitochondrial respiratory chain [5].
Many of these potential anesthetic targets are predicted to be
dominated by alpha helical structure, particularly in their
membrane-spanning regions. These regions typically contain bun-
dles of helices, associating side-to-side in a parallel or antiparallel
manner. In the rare cases where genetic or biochemical mapping
data are available, the anesthetic-sensitive residues have been
found to be located in these membrane-spanning regions, in areas
predicted to lie between adjacent subunits [6,7,8,9,10,11,12,13].
However, the details of these binding sites, including how they
recognize anesthetics, will not be fully appreciated until high-
resolution structures are obtained for pharmacologically relevant
targets. Unfortunately, this goal may not be realized for some time,
owing to the difficulties associated with expressing, purifying, and
crystallizing large eukaryotic membrane proteins [14].
Until structures become available for mammalian membrane-
bound anesthetic targets, it can be fruitful to use surrogate proteins
as models for protein-anesthetic recognition. Several soluble
proteins of known structure contain binding sites that recognize
a wide variety of anesthetic agents, including serum albumin [15],
firefly luciferase [16], and synthetic peptides [17]. In addition,
GLIC, a prokaryotic homolog of eukaryotic ligand-gate ion
channels, has been shown to be inhibited by various anesthetics
[18], and its structure has recently been determined in complex
with two such drugs [19]. However, an arguably more useful
surrogate is horse-spleen apoferritin, because it binds both inhaled
and injected general anesthetics with affinities that are clinically
relevant, and which correlate well with clinical measures of
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available, very stable, and crystallizes readily, making for a
tractable model system.
We have termed apoferritin a ‘‘unitary’’ binder of anesthetics
because its single binding site is able to recognize anesthetic
compounds belonging to widely varying chemotypes [21]. These
compounds are bound with affinities that correlate well with their
potencies, arguing that the apoferritin site shares physicochemical
features with the binding sites in clinically relevant targets.
Furthermore, in a homologous series of analogs of the injectable
anesthetic propofol, each compound’s affinity for apoferritin was
found to be strongly correlated with its ability to potentiate GABA
responses at the GABAA receptor [22], suggesting that the
apoferritin anesthetic binding site may specifically resemble that
of the GABAA receptor. Selectivity for this chemiarchitecture is
demonstrated by the fact that non-immobilizers do not bind the
apoferritin site [23]. In addition to these pharmacological
similarities, the apoferritin site may share topological elements in
common with anesthetic binding sites in human membrane-bound
ion channels, since the apoferritin site lies at the interface between
two helical bundle domains.
Barbiturates were discovered during the first decades of the
twentieth century, and rapidly became widely used as sedatives
and general anesthetics [24]. Since reaching their heyday in the
1930’s and 1940’s, they have been largely replaced by propofol
and other sedatives, such as the benzodiazepines, which are less
prone to overdose, abuse, misuse and addiction. However,
phenobarbital is still used as a sleep aid, thiopental is still used
as an induction agent, and pentobarbital is still widely used in
veterinary practice (see Figure 1 for the chemical structures of
these compounds). The molecular details of how barbiturates
interact with their targets remain largely unknown, as there exist
no structures for protein-barbiturate complexes in the Protein
Data Bank. Here, we show that pentobarbital and thiopental, like
several other general anesthetics, bind to a common cavity in
apoferritin. This result further supports the notion that apoferritin
is a unitary recognizer of GABAergic anesthetics, and validates the
protein’s use as a surrogate model for the clinically relevant
binding sites of general anesthetics.
Results
Apoferritin binds barbiturates
Isothermal titration calorimetry (ITC) was used to confirm that
phenobarbital, pentobarbital, and thiopental bind directly to
apoferritin, with dissociation constant values lying in the range 10
to 700 mM (Table 1). Thiopental binds most tightly; the affinity of
pentobarbital is approximately 6-fold lower, while phenobarbital’s
affinity for apoferritin is 50-fold lower than that of thiopental. All
compounds display favorable enthalpies of binding. The affinities
of the barbiturates for apoferritin are very similar to reported EC50
values for general anesthesia in mammals and for enhancement of
GABAA activity (Table 1).
The methylbutyl chain found in pentobarbital and thiopental
can exist as one of two optical isomers, with the stereocenter at the
branch point between the methyl and butyl groups; the difference
in anesthetic potency between the two stereoisomers is small
(roughly 2-fold), with the S-enantiomer being the more potent
[25]. Racemic mixtures of these compounds are used clinically. To
probe the effect of barbiturate stereochemistry on apoferritin
binding, we purified the optical isomers of thiopental and
measured their binding affinities using ITC (Table S1). The S-
enantiomer was found to bind 1.5-fold more tightly than the R-
form, mirroring the clinically observed difference in potencies.
Structure determination
To determine the site at which the barbiturates bind, apoferritin
was co-crystallized with thiopental and pentobarbital and the
crystal structures of the complexes were determined (Table 2;
because of phenobarbital’s low affinity for apoferritin, the crystal
structure of this complex was not attempted). The crystals that we
obtained had space groups and unit cells isomorphous with
previous apoferritin structures, and structure determination via
molecular replacement confirmed the same crystal system. Initial
electron density maps contained clear density in the anesthetic
binding site, confirming the presence of the barbiturate ligands.
For both pentobarbital and thiopental, the initial electron density
of the ligand was distinct from that seen in the unliganded
structure, where the binding site contains four water molecules
[21]. In both complexes, the electron density corresponding to the
barbiturate ring was more distinct than the density for the alkyl
substituents, suggesting that the ring structure may be held more
tightly than the ethyl and methylbutyl chains.
Apoferritin forms a highly symmetric 24-mer. Each protomer in
the oligomer forms a helical bundle composed of four long
antiparallel helices, with a fifth helix capping one end of the
bundle, and an extended crossover strand connecting the second
and third helices. Although our apoferritin preparation contains
Figure 1. Chemical structures of selected barbiturates.
doi:10.1371/journal.pone.0032070.g001
Table 1. Binding, physical, and activity data for barbiturates.
Thiopental Pentobarbital Phenobarbital
Dissociation constant Kd for
apoferritin binding (mM)
11.060.9 64.365.5 672627
Enthalpy of binding to
apoferritin (kcal/mol)
a
27.360.4 24.460.7 —
apoferritin cavity volume (A ˚3) 388.6 407.6 —
Ligand volume (A ˚3) 223.9 210.5 211.3
Packing density 0.58 0.52 —
EC50 for anesthesia (mM) 25
b 50
b 590
c
EC50 for GABA potentiation
(mM)
20
d 30–60
d, e, f 300–900
e, f
logP
g 2.9 2.1 1.5
aBecause of the low affinity of phenobarbital for apoferritin, it was not possible
to obtain a satisfactory estimate of the molar binding enthalpy.
b[16].
c[41].
d[42].
e[43].
f[44].
gCalculated using XLOGP3 [45].
doi:10.1371/journal.pone.0032070.t001
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this structure (see Methods). The overall structure of the
apoferritin molecule is not significantly altered in response to
barbiturate binding; root-mean-square differences in Ca positions
are less than 0.1 A ˚ when either barbiturate complex structure is
superimposed upon the unliganded apoferritin structure.
The apoferritin anesthetic binding site is located within a cavity
at the interface between two protomers; the cavity is largely buried
within the protein interior, but is connected to the protein surface
(and thus to bulk solvent) via two small funnel-shaped openings.
The two protomers forming the cavity are related by a 2-fold
symmetry axis that runs through the center of the binding site.
Hence, equivalent residues from both subunits contribute to the
cavity surface, and an anesthetic molecule bound within this cavity
has the potential to interact with both copies of a given residue.
The symmetry of the binding site dictates that the ligand can
occupy two positions, related to one another by a 180u rotation.
These two positions overlap, so that in a given cavity the ligand
can adopt only one of the two symmetry-related conformations;
however, because the electron density is averaged over the entire
crystal, the map will reflect both conformations.
Thiopental binding site
Thiopental interacts with apoferritin via a hydrogen bond, a
possible electrostatic interaction, and multiple hydrophobic
contacts. The hydrogen bond is formed between the ring nitrogen
of the barbiturate and Ser-27 (Figure 2A). The geometry of this
hydrogen bond is close to ideal; the oxygen-nitrogen distance is
2.87 A ˚ and the serine’s hydroxyl oxygen lies close to the plane of
the barbiturate ring (0.002 A ˚ perpendicular distance from the
oxygen to the ring plane). The angle formed by the barbiturate
ring nitrogen, the serine hydroxyl oxygen, and the serine beta
carbon is 111.9u, also highly favorable [26].
An electrostatic interaction may occur between the barbiturate
ring sulfur and the guanidino group of Arg-59. The Arg-59 side
chain is present in two conformations: one similar to the ‘‘closed’’
conformation seen in the water-bound (unliganded) apoferritin
structure, the other to the ‘‘open’’ conformation found in the
apoferritin-propofol complex structure [21]. In the pentobarbital
complex, the closed conformer of the arginine places a guanidino
nitrogen 3.8 A ˚ from the barbiturate ring sulfur. No electron
density is observed for any other nearby counter-ion. This sulfur
atom is capable of a keto-enol tautomeric transition, and is
assigned a formal charge of -1 in the enol form. We cannot directly
determine whether the drug adopts the keto or enol form in our
structure, because the structural differences between the two forms
are minute. Although the close presence of the Arg-59 guanidino
group suggests that the sulfur could possess at least partially
negative character, the generally hydrophobic nature of the ligand
binding pocket makes it likely that the ligand adopts the less polar
keto form.
Hydrophobic interactions occur between the protein and the
ethyl and methylbutyl chains that extend from the thiopental ring.
The ethyl group of the thiopental ligand sits atop a hydrophobic
patch within the binding site that is created by the side chains of
Tyr-28 and Leu-81 from one apoferritin monomer and Leu-24
and Leu-81 from the symmetry-related apoferritin molecule. The
atoms in the ligand and protein that participate in this interaction
Table 2. Crystallographic data collection and refinement
statistics.
Pentobarbital Thiopental
Data collection
Spacegroup F432 F432
Wavelength (A ˚) 0.977 1.542
Resolution range
a 45.62-1.90
(1.97-1.90)
41.79-2.00
(2.05-2.00)
Cell constants a=b=c(A ˚) 182.48 182.18
Number of unique reflections 21,095 33,018
Mean redundancy 34.09 (34.09) 21.2 (8.5)
Completeness (%) 100.0 (100.0) 99.7 (98.4)
RMERGE 0.109 (0.527) 0.061 (0.616)
Mean I/o ´(I) 20.0 (7.8) 40.6 (3.8)
Refinement
RWORK 0.174 0.172
RFREE 0.208 0.193
Number of atoms
total 1575 1539
protein 1346 1344
ligand 16 16
water 197 164
metal 6 5
other solvent atoms 10 10
RMS deviation from ideality
bonds (A ˚) 0.007 0.007
angles (deg) 0.959 0.936
aValues in parentheses correspond to the outermost resolution shell.
doi:10.1371/journal.pone.0032070.t002
Figure 2. Stereoviews showing the anesthetic binding site of
apoferritin with A) thiopental and B) pentobarbital. The
hydrogen bond between the drug and Ser-27 is shown as a black
dashed line. In both images the ligands are depicted as sticks; color
code: carbon, yellow; nitrogen, blue; oxygen, red; and sulfur, magenta.
The electron density shown is 2Fo-Fc density calculated from the final
refined structures, contoured at sigma level of 0.8 and carved around
the ligands. Figures 2 and 3 were generated using PyMOL (The PyMOL
Molecular Graphics System, Schro ¨dinger, LLC).
doi:10.1371/journal.pone.0032070.g002
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from 3.7 to 4.5 A ˚. The closest polar group to ligand’s ethyl chain is
the carbonyl group of Leu-24, which is 5.0 A ˚ from the thiopental.
The methylbutyl group of the ligand lies in the center of the
hydrophobic cavity, with its tail extending into the funnel-shaped
aperture that connects the anesthetic binding site with the surface
of the protein. It packs against methylene groups of the Arg-59
side chain; this arginine side chain forms much of the cap that
closes off the anesthetic binding site from solvent. Both
stereoisomers were consistent with the electron density in the
binding site; given their similar affinities, the ligand was modeled
as a mixture of R- and S-forms of the molecule. The majority of
the methylbutyl group lies in a position that overlaps electron
density corresponding to the barbiturate ring of the symmetry-
related copy of the ligand. This fact, together with the presumed
presence of different optical isomers, means that the precise
positions of the atoms in the methylbutyl group are not well
determined.
Pentobarbital binding
Pentobarbital binds apoferritin in a manner that is directly
equivalent to that seen with thiopental. A similar hydrogen bond is
seen between a barbiturate ring nitrogen and the hydroxyl moiety
of Ser-27 (nitrogen-oxygen distance=2.83 A ˚; distance between
the serine hydroxyl oxygen and the plane of the barbiturate
ring=0.4 A ˚; angle formed by Cb27—Oc27—barbiturate ring
nitrogen=111.2u; Figure 2B). As is the case with thiopental, Arg-
59 adopts two alternate conformers in the pentobarbital complex
structure, and a guanidino nitrogen of one conformer lies 3.6 A ˚
from the ring oxygen, contributing a possible electrostatic
component to pentobarbital recognition. The ethyl and methyl-
butyl chains of the pentobarbital molecule lie in similar positions to
those occupied by their counterparts in the thiopental structure,
and make similar interactions with the protein. An apparent steric
clash exists between the methylbutyl group and the hydroxyl
group of Ser-27 (carbon-oxygen distance 2.6 A ˚). This may merely
reflect a lack of precision in positioning the atoms in the
methylbutyl group, similar to that encountered with thiopental;
alternatively, this copy of Ser-27 (the symmetry mate of the Ser-27
side chain that is hydrogen bonding to the barbiturate ring) may
adopt an alternate conformer that we were unable to discern in the
electron density.
Discussion
A consensus now exists that general anesthetics exert their effects
through binding and modulating the activities of ion channels and
other integral membrane proteins. Unfortunately, despite recent
successes [19], it remains difficult to visualize the details of how
anesthetics interact with these targets, since integral membrane
proteins are challenging systems for high resolution structural
studies. Until structure determination for membrane proteins
becomes routine, surrogate model systems will remain valuable
tools for advancing our understanding of how proteins recognize
anesthetics. Apoferritin arguably represents one of the most useful
such models now available. Its structure is well characterized, and it
recognizes a wide variety of inhaled and intravenous anesthetic
agents. Importantly, apoferritin’s binding affinities for different
anesthetics are comparable to clinically relevant concentrations; in
contrast, the prokaryotic ion channel GLIC displays very different
patterns of anesthetic recognition than mammalian anesthetic
targets [18], despite possessing a pentameric architecture that is
similar to those of known mammalian targets such as the
acetylcholine and GABAA receptors [27].
Barbiturates can now be added to the list of general anesthetics
recognized by apoferritin, providing a second example of
recognition of an injected general anesthetic (the first being
propofol). Interestingly, both propofol and the barbiturates act
largely via GABA transmission, as both can directly gate and
potentiate the inhibitory GABAA receptor. For propofol and
related compounds, affinity for apoferritin is very close to the EC50
for GABA potentiation [21]; the same appears true for
barbiturates. EC50 values for GABA potentiation by thiopental,
pentobarbital, and phenobarbital are close to their Kd values for
apoferritin (Table 1), bolstering the argument that the anesthetic
binding sites on apoferritin and the GABAA receptor share
structural and physicochemical similarity.
Within the barbiturate class, different compounds potentiate
GABA effects and mediate anesthesia with different potencies;
these differences are largely mirrored in their affinities for
apoferritin. It is therefore interesting to ask which features of the
apoferritin-barbiturate interaction are responsible for these
differences in affinity. Thiopental and pentobarbital are iso-
structural, differing only at a single atom, and adopt essentially
identical orientations and conformations within the apoferritin
binding site. The slightly larger sulfur atom gives thiopental a
slightly larger volume and surface area, but such trivial size
differences seem unlikely to explain an approximate five-fold
difference in affinity. A more likely explanation is thiopental’s
more hydrophobic nature, as reflected by its higher partition
coefficient (Table 1). If indeed the apoferritin binding site
preferentially recognizes thiopental on the basis of its lower
polarity, then this argues that the form of the anesthetic bound to
the protein is the less polar keto tautomer.
Phenobarbital has a substantially lower affinity for apoferritin
than either thiopental or pentobarbital. While it is similar to in size
to the other two compounds, it is more polar than either,
consistent with an apoferritin binding site that prefers less polar
ligands. Also, modeling suggests that phenobarbital’s rigid phenyl
ring could lead to steric clashes between the ligand and the
protein; the methylbutyl substituent of thiopental and pentobar-
bital, while not much smaller than the phenyl ring, is substantially
more flexible, and hence more easily accommodated within the
binding site.
There are both similarities and differences in how apoferritin
recognizes barbiturates versus other, chemically distinct classes of
anesthetics (Figures S3 and S4). Similarity can be found in a
common binding area shared by haloalkanes, halogenated ethers,
propofol analogs, and barbiturates; this area is a small hydropho-
bic patch created by Tyr-28, Leu-24, and Leu-81 (Figures 3, S3,
and S4). In the barbiturate complexes this hydrophobic patch
interacts with the ethyl substituent, in the propofol complexes this
position is occupied by an aromatic ring, and in the halothane
and isoflurane complexes it is occupied by two fluorine atoms
(Text S1).
Differences in ligand recognition exist between the apoferritin-
barbiturate and apoferritin-propofol complex structures. Even
though both propofol and the barbiturates contain aromatic rings,
the planes of these rings are rotated nearly 90 degrees between the
two classes of drug. The highly hydrophobic propofol analogs bind
with their hydroxyl groups (their only potential hydrogen bond
donor/acceptor) pointing toward the opening of the protein
cavity, away from the cavity walls, and do not use this hydroxyl
group to interact with the protein. In contrast, the position of the
barbiturates allows them to hydrogen bond with Ser-27 of
apoferritin. This hydrogen bond, together with a potential polar
interaction between the barbiturate ring and Arg-59, are the most
notable differences between how apoferritin recognizes the
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Apoferritin appears to rely principally upon van der Waals
interactions when binding other anesthetics, with little or no
contribution from polar interactions. van der Waals interactions
do contribute to recognition of the barbiturates, particularly
between the alkyl substituents of the drugs and hydrophobic side
chains of the protein. However, the favorable enthalpies of binding
provided by the polar interactions are likely to substantially exceed
the contribution from these van der Waals interactions, and
dominate the binding energies.
The exploitation of polar interactions for barbiturate recogni-
tion has interesting implications for anesthetic binding. First, it
means that the apoferritin site (and probably any site that responds
to multiple classes of general anesthetics) must be versatile, and
able to rely to differing degrees upon hydrophobic versus polar
interactions, depending upon the ligand. Such an amphipathic site
should be able to recognize different targets in a versatile manner
[28]. For example, apoferritin contains polar side chains within its
hydrophobic cavity, but these side chains are capable of
interacting with partners other than the ligand. In the absence
of ligand, the hydroxyl group of Ser-27 can hydrogen bond with a
backbone carbonyl oxygen of the protein; in the presence of
barbiturates, this same side chain interacts with the drug. In this
way, anesthetics can competitively alter hydrogen-bonding
patterns within their binding site, and potentially affect protein
stability or dynamics [29].
Another way in which proteins can flexibly recognize different
ligands is by stretching or shrinking their binding pockets.
However, proteins are limited in the degree to which they can
expand or contract a cavity before their structural integrity is
compromised. Thus, the volume of the anesthetic-binding cavity
in apoferritin varies to some degree when binding different ligands,
but affinity is reduced for ligands that are too large to be
comfortably accommodated within the acceptable range of cavity
volumes. Interestingly, thiopental and pentobarbital are larger
than other apoferritin anesthetic ligands examined to date, and yet
they are still bound with reasonably high affinity. We suggest that
an explanation lies with the polar interactions that the barbiturates
make within the apoferritin binding pocket.
For ligands that rely solely on van der Waals interactions for
recognition, larger ligands have larger surface areas, and can
therefore develop larger favorable enthalpies of binding; however,
they will also be bound more snugly in the binding pocket,
imposing an entropic penalty. At some point, the incremental
enthalpic gains associated with increased surface area will be
outweighed by the increasing entropic penalty. For nonpolar
ligands, the competing enthalpic and entropic effects lead to
maximum affinity when the ligand’s volume corresponds to
approximately 50–60% of the available cavity volume [30]. In
contrast, strong polar interactions between a ligand and its target
contribute substantially larger favorable enthalpies of binding than
do van der Waals interactions, and so when polar interactions are
present, greater losses in conformational entropy (and hence
higher packing densities) can be tolerated. This appears to be the
case with anesthetic binding to apoferritin (Figure 4). For propofol-
like compounds that make no polar interactions with the protein,
affinity decreases when ligand volume is increased beyond 50% of
the cavity volume [21]. However, for compounds like thiopental
and pentobarbital that make polar contacts with apoferritin,
ligands can fill well over 50% of the available cavity volume, yet
Figure 3. Diverse general anesthetics utilize a common binding site in apoferritin. A) Orthogonal views of the apoferritin dimer, shown as
a partially transparent molecular surface encasing a cartoon representation of the backbone. The anesthetic binding site is marked by thiopental,
which is shown in a red space-filling representation. B) Stereo view showing a close-up of the anesthetic binding site, in an orientation similar to that
seen in the left half of the upper panel. Four different general anesthetics are shown in ball-and-stick representations: Thiopental (yellow); propofol
(magenta); isoflurane (cyan); and halothane (orange). The protein backbone is shown in blue, while selected protein side chains are shown in light
gray. All four compounds, despite belonging to different chemotypes, utilize the same binding cavity, in which their positions overlap extensively.
doi:10.1371/journal.pone.0032070.g003
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extract the loss in ligand conformational entropy from our
calorimetric data, since calorimetric estimates of DS include
contributions from the displacement of water.
We caution that understanding why a particular anesthetic
binds with high affinity to a given target will not necessarily
provide insights into general anesthesia, since anesthetic side
effects are presumably also mediated by interactions with protein
targets, some of which may occur with high affinity. However, the
side-effect profiles of currently-used anesthetics vary considerably,
suggesting that, unlike anesthetics’ clinically useful effects, side
effects tend to derive from chemotype-specific interactions.
Therefore, targets that recognize many different anesthetic
chemotypes are likely to reveal binding properties that are relevant
to the production of the anesthetized state.
In summary, we present the first structures of barbiturates
bound to a specific protein target. They add support to the notion
that direct protein interactions subserve anesthetic effects. Further,
these data emphasize that apoferritin is a unitary anesthetic
binder, capable of accommodating different general anesthetic
chemotypes. Its binding site contains a three-dimensional
distribution of amphipathic features that allow recognition of a
diverse collection of anesthetic ligands with remarkably high, and
clinically relevant, affinity. Thus, it would seem that the apoferritin
site can be considered a prototypical anesthetic binding site, and
used for purposes as diverse as database mining or screening of
novel anesthetic candidates.
Materials and Methods
Materials
Apoferritin, thiopental, pentobarbital, and phenobarbital were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Optical
isomers of thiopental were isolated using a Nucleodex Beta-PM
chiral column (106250 mm; 5 mm pore size), using a mobile phase
of 40% acetonitrile in 1.0% triethylammonium acetate, pH 4 and
a flow rate of 0.6 mL/min.
Isothermal titration calorimetry
ITC measurements were carried out essentially as previously
described [20], using a MicroCal VP-ITC instrument (North-
ampton, MA). The sample cell (1.43 mL) contained 10 mM
apoferritin 24-mer that had been dialyzed overnight against
20 mM NaHPO4 pH 7.0 containing 130 mM NaCl. The
reference cell contained water. Ligands were dissolved in the
dialysate, to a final concentration of 0.45–1.6 mM, and filtered
through 0.2 mm PTFE syringe filters. The titration volumes were
12 mL for the first injection, followed by 14 mL each for the
subsequent injections. Sequential titrations were performed until
the heat change was essentially constant. Sequential titrations were
linked using ConCat32 software (Microcal, Inc.), and corrections
were applied for heat changes due to buffer-buffer, buffer-protein,
and ligand-buffer dilutions. Representative ITC traces are shown
in Figure S5.
Protein crystallization and data collection
Apoferritin was purified by gel filtration chromatography with
0.2 M NaOAc, pH 5.0 as the mobile phase, and concentrated to a
final concentration of 12 mg/mL for co-crystallization with
thiopental. For co-crystallization with pentobarbital, apoferritin
from Sigma was diluted with deionized water to a final con-
centration of 12 mg/mL. 1–2 mL of reservoir solution containing
0.2–1.6 M (NH4)2SO4 and 0.1–0.275 M CdSO4 were mixed with
equal volumes of apoferritin solution and equilibrated over 0.7–
1 mL reservoir solution at 18uC. Thiopental (0.5 mM) was
dissolved directly in the reservoir solutions prior to crystallization
trials, while pentobarbital (1–3 mM) was added to the protein
solution and incubated for 30 min prior to crystallization trials. All
solutions were pre-filtered through a 0.2 mm filter. Crystals
appeared within 1–2 weeks and grew to a final size of 200–
300 mm. Single crystals with well-defined edges were cryopro-
tected using reservoir solution containing 0.5–3 mM ligand and
30% glycerol and flash-cooled in liquid nitrogen for data
collection. Diffraction data were collected at beamline X6A of
the National Synchrotron Light Source, and integrated using
d*TREK [31].
Structure determination
Molecular replacement was carried using a poly-alanine search
molecule derived from the unliganded apoferritin structure, with
all water molecules and metal ions removed; both the thiopental
and pentobarbital complex structures were determined using the
PHASER molecular replacement program [32]. Initial 2FO-FC
and FO-FC electron density maps showed features corresponding to
side chains, water molecules, and metal ions, as well as the
barbiturate compounds bound in the anesthetic binding site. The
structures were refined by iteratively cycling between manual
rebuilding and automated refinement. Atomic coordinates of side
chains, water molecules and cadmium ions were built into 2FO-FC
electron density maps using COOT [33]. The atomic positions,
temperature factors and occupancies were refined using PHENIX
[34] and REFMAC [35]. Towards the end of the refinement the
barbiturate compounds were built into electron density at the
anesthetic binding site. The electron density for both structures
indicated the presence of two optical isomers, which were
incorporated into the models. The quality of phase information
was assessed by generating omit maps with PHENIX and
SFCHECK [36], and stereochemistry was validated using
PROCHECK [37] and the validation tools within COOT.
Commercially available apoferritin is a mixture of heavy and
light chains, in an approximate mole ratio of 1:6; only the light
chain can be observed in the electron density map, as has
Figure 4. The packing density/affinity relationship for barbi-
turates is offset from that of the propofol-like compounds,
interpreted here as the addition of an entropic penalty offset
by new enthalpic gains. Shown is the relationship between packing
volume (fraction of cavity volume occupied by ligand) and affinity
(dissociation constant, Kd) for apoferritin. The filled triangles represent a
series of propofol analogs, for which a linear dependence of affinity
upon packing density has been documented [21]. The open circles
represent the barbiturates (P, pentobarbital; T, thiopental).
doi:10.1371/journal.pone.0032070.g004
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factors have been deposited with the PDB (thiopental, PDB ID
3RD0; pentobarbital, PDB ID 3RAV).
Structure analysis
Anesthetic binding pocket volumes were calculated as described
([21]; Text S1; Figures S1 and S2) using VOIDOO [39] and
standard values for atomic radii [40]. Ligand volumes were
obtained by minimizing ligand structures with PHENIX [34],
after which the volume of the energy-minimized ligand structure
was calculated using VOIDOO.
Supporting Information
Figure S1 Calculated cavity volume versus VOIDOO
iteration, for two apoferritin structures. In early cycles,
where the grid used to calculate volume is coarse, the determined
cavity volumes are underestimated. With increasing iterations the
grid becomes finer and detected cavity volume increases and
eventually converges. The small diamonds represent ten random
orientations of the unliganded apoferritin structure (PDB ID
3F32); the crosses represent ten random orientations of the
pentobarbital structure. The curves represent gnuplot fits of
equation (1) to the data (see Text S1). The arrows indicate periods
of local decline, which may cause the VOIDOO program to
terminate prematurely.
(TIF)
Figure S2 Comparison of two methods for determining
apoferritin cavity volume. The crosses represent volumes
calculated by choosing ten random orientations of the molecule,
allowing VOIDOO to run until program termination, and
averaging the volumes generated for each orientation. The
squares represent volumes calculated from v(n) curves fitted to
the VOIDOO output, using n=25 (see Text S1). The overall
trend is maintained for the two methods, but volumes calculated
by averaging cavity volumes reported after program termination
were in all cases smaller than volumes calculated by curve fitting.
PDB ID codes of apoferritin-anesthetic complexes contributing to
this figure: 3F32, unliganded; 1XZ1, halothane; 1XZ3, isoflurane;
3F33, propofol; 3RD0, thiopental; 3RAV, pentobarbital; 3F34 &
3F35, 2,6-diethyl phenol; 3F36, 2-isopropyl phenol; 3F37 & 3F38,
2,6-dimethyl phenol; 3F39, phenol.
(TIF)
Figure S3 Stereo diagrams showing the hydrophobic
anesthetic binding cavity of apoferritin bound to diverse
general anesthetics. Pentobarbital is shown in both images, to
allow direct comparison. The molecular surface of the cavity is
shown as a semi-transparent tan surface that partially obscures
Leu-24. A) The pentobarbital-apoferritin complex; both optical
isomers are shown in this panel, in yellow and cyan. (In subsequent
panels, only the more abundant isomer of pentobarbital is shown,
for the sake of clarity). B) An overlay of propofol (yellow, PDB
entry 3F33) and pentobarbital (cyan).
(TIF)
Figure S4 Stereo diagrams showing the hydrophobic
anesthetic binding cavity of apoferritin bound to diverse
general anesthetics (continued from Figure S3). Pento-
barbital is included in both images, to allow direct comparison.
The molecular surface of the cavity is shown as a semi-transparent
tan surface that partially obscures Leu-24. A) Overlay of halothane
(yellow) and pentobarbital (cyan). B) Overlay of isoflurane (yellow)
and pentobarbital (cyan).
(TIF)
Figure S5 Representative ITC traces for the binding of
barbiturates to apoferritin. Panel A, thiopental; panel B,
pentobarbital; panel C, phenobarbital.
(TIF)
Table S1 Apoferritin binding affinities of the optical isomers of
thiopental.
(DOC)
Text S1 Details of cavity volume calculations, and a
comparison of how different general anesthetics to the
common apoferritin pharmacophore.
(DOC)
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